Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanghuangporusbaumii tablets for immune regulation after chemotherapy in colorectal cancer
ChiCTR2100049792Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jan 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sanghuangporus baumii in colorectal cancer (CRC) and immunocompromise (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Immunocompromised control ratio, Immune function index and 2 more. Started Jan 2021; status: recruiting.
02
Drugs
Sanghuangporus baumii
03
Conditions
colorectal cancer (CRC)immunocompromise
Beyond the preview
Go deeper on ChiCTR2100049792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049792.